Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Pia Sormani

Showing results (1-10 of 389) with videos related to

Pageof 39
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 17, 2016
Subgroup analysis in MS trialsMaria Pia Sormani
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 7, 2017
Prognostic factors versus markers of response to treatment versus surrogate endpoints: Three different conceptsMaria Pia Sormani
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 10, 2017
Indirect comparisons of treatment effects: Network meta-analysesMaria Pia Sormani
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 10, 2017
The most frequently asked question to a statistician: The sample sizeMaria Pia Sormani
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 29, 2017
Why non-inferiority is more challenging than superiority?Maria Pia Sormani
The Lancet. Neurology|May 4, 2020
An Italian programme for COVID-19 infection in multiple sclerosisMaria Pia Sormani,
Journal of the Neurological Sciences|January 29, 2010
The Will Rogers phenomenon: the effect of different diagnostic criteriaMaria Pia Sormani
Multiple Sclerosis and Related Disorders|April 17, 2015
Modeling the distribution of new MRI cortical lesions in multiple sclerosis longitudinal studies by Sormani MP, Calabrese M, Signori A, Giorgio A, Gallo P, De Stefano N [PLoS One 2011;6(10):e26712. Epub 2011 October 20]Maria Pia Sormani
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 4, 2019
Real-world studies provide reliable comparisons of disease modifying therapies in MS - NoMaria Pia Sormani
The Lancet. Neurology|June 8, 2013
MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trialsMaria Pia Sormani, Paolo Bruzzi
Pageof 39

Showing results (1-10 of 389) with videos related to

Sort By:
Pageof 39
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 17, 2016
Subgroup analysis in MS trialsMaria Pia Sormani
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 7, 2017
Prognostic factors versus markers of response to treatment versus surrogate endpoints: Three different conceptsMaria Pia Sormani
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 10, 2017
Indirect comparisons of treatment effects: Network meta-analysesMaria Pia Sormani
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 10, 2017
The most frequently asked question to a statistician: The sample sizeMaria Pia Sormani
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 29, 2017
Why non-inferiority is more challenging than superiority?Maria Pia Sormani
The Lancet. Neurology|May 4, 2020
An Italian programme for COVID-19 infection in multiple sclerosisMaria Pia Sormani,
Journal of the Neurological Sciences|January 29, 2010
The Will Rogers phenomenon: the effect of different diagnostic criteriaMaria Pia Sormani
Multiple Sclerosis and Related Disorders|April 17, 2015
Modeling the distribution of new MRI cortical lesions in multiple sclerosis longitudinal studies by Sormani MP, Calabrese M, Signori A, Giorgio A, Gallo P, De Stefano N [PLoS One 2011;6(10):e26712. Epub 2011 October 20]Maria Pia Sormani
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 4, 2019
Real-world studies provide reliable comparisons of disease modifying therapies in MS - NoMaria Pia Sormani
The Lancet. Neurology|June 8, 2013
MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trialsMaria Pia Sormani, Paolo Bruzzi
Pageof 39